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Abstract 
Patients with Crohn’s disease require long-term therapy and physician follow-up to treat 
symptoms, minimize complications of the disease, and address side effects that may 
occur due to therapeutic interventions. Once stabilized, it is not unusual for patients to 
question the need for continued therapy. This may be related to various factors including 
poor disease awareness, lack of adequate communication between the physician and the 
patient, not wanting to take medications chronically, and/or financial issues among a 
host of other possibilities. However, nonadherence can have a serious impact on 
morbidity and mortality in patients with Crohn’s disease. This case illustrates the 
management and stabilization of a patient with active Crohn’s disease and the use of 
diagnostic serological testing to aid in disease risk assessment and treatment guidance. 
 
Introduction 
In the absence of ‘curative’ treatment options, patients with Crohn’s disease require 
continuous therapeutic management and monitoring by a physician [1]. Therapeutic 
choices depend on location of inflammatory lesions, severity of disease, and 
complications [1]. Treatment goals for Crohn’s disease, like those for many other chronic 
diseases, include eradication of disease-related symptoms and restoration of the patient’s 
quality of life while minimizing complications or therapy-related toxicities [1]. Success 
depends in part on patient adherence to the therapeutic regimen, which is influenced by 
many factors including the physician-patient relationship, disease awareness, effectiveness 
of the prescribed regimen, and adverse events associated with treatment. 
Patients often doubt the severity of their Crohn’s disease [2] and, therefore, empirical 
evidence of their disease and an objective measurement of disease severity can be a 
powerful tool to motivate adherence, especially after symptoms improve. The case 
presented here was chosen to illustrate the importance of ongoing therapy to a positive 
outcome based on objective diagnostic findings and patient education.  
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Case Report 
A 21-year-old man was admitted to the emergency department of a hospital in December 2007 
complaining of nausea/vomiting and periumbilical pain. Computed tomography of the abdomen/pelvis 
revealed ileal thickening and a small bowel obstruction. The differential diagnosis was infectious 
enteritis versus Crohn’s disease. The patient was admitted to the hospital and treated with nasogastric 
suction, intravenous fluids, and antibiotics. He subsequently improved and was discharged. 
Soon after, the patient presented at our office with complaints of recurrent abdominal pain, 
new-onset diarrhea, and rectal bleeding. A colonoscopy in April 2008 demonstrated ulcerations of the 
ileum and colon consistent with Crohn’s disease; the ileum was notably stenotic, and only the distal few 
centimeters could be visualized (fig. 1). A small bowel follow-through study with barium contrast 
showed the stenoses and ulcerations extending over the distal 30 cm of the ileum and confirmed a 
diagnosis of Crohn’s disease. Treatment with mesalamine 4 g/day and a 14-day course of metronidazole 
relieved the abdominal pain and bleeding, but the diarrhea persisted. 
Over the next 2 weeks, the patient developed epigastric pain and nausea and was admitted to the 
hospital for severe pain. A diagnosis of pancreatitis likely due to the mesalamine prompted 
discontinuation of the drug and initiation of budesonide 9 mg/day. Symptoms of pancreatitis 
subsequently improved, and the patient was discharged from the hospital after a short stay. Over the 
next 3 weeks, the diarrhea, bleeding, and pain resolved. 
However, by the end of August 2008, the diarrhea and cramping periumbilical pain recurred, and an 
immunomodulator was added to the therapeutic regimen. Ten days later, the patient was admitted to 
the hospital with a high fever (103°F) associated with elevated liver enzymes and lymphopenia. Workup 
for bacterial infection was negative, and a viral illness was presumed. The immunomodulator was 
discontinued as it was presumed that the lymphopenia had made the patient susceptible to the infection.  
In November 2008, at the follow-up appointment in the physician’s office, a lengthy discussion with 
the patient included the care of Crohn’s disease and the risks and benefits of biologic therapy. A 
decision was made to initiate induction therapy with the anti-tumor necrosis factor (TNF) agent 
adalimumab 160 mg s.c. then 80 mg s.c. 2 weeks later, followed by maintenance therapy at a dose of 
40 mg s.c. every 2 weeks. By March 2009, the patient was in clinical remission and had regained 15 lb. A 
follow-up colonoscopy demonstrated complete healing of the colonic mucosa and significant ileal 
healing as well (fig. 2). 
At this point, the patient questioned the need for long-term treatment with adalimumab. He 
preferred to stop the medication because he was feeling well and because he was concerned about the 
potential for adverse effects. A Prometheus IBD Serology 7 test was ordered to help assess the need for 
ongoing therapy based on serologic markers. Results revealed elevations of the following biomarkers for 
Crohn’s disease: ASCA (both IgA and IgG), anti-OmpC IgA, anti-CBir1, and inflammatory bowel 
disease (IBD)-specific pANCA (table 1). After additional discussion about the prognostic value of 
elevations of multiple markers and the high risk for disease progression, the patient agreed that 
continued anti-TNF therapy was indicated. The patient continues to feel well without adverse effects of 
therapy. 
Discussion 
Several studies have examined nonadherence to treatment for IBD. In one such 
prospective study, Cerveny et al. [2] found that 38.9% of patients were intentionally 
nonadherent to their IBD regimen during the 2 weeks prior to being interviewed and that 
patients’ disease awareness and medication knowledge are important influences on 
adherence. 
Serologic testing such as with the Prometheus IBD Serology 7 panel has evolved over 
time – from its initial use in helping differentiate ulcerative colitis from Crohn’s disease to 
further evaluating indeterminate colitis, stratifying disease, predicting the potential course 
of IBD, determining more severe disease phenotypes, and guiding treatment based on the 
prognosis of the patient. Serologic testing can determine the level of immune reactivity to 
various markers of disease and, therefore, can be used to predict an increased risk of  
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complicated disease requiring ongoing treatment [3]. The serologic results for our 
21-year-old patient were communicated clearly to him, improving his disease awareness 
and ability to make informed decisions during treatment. The results facilitated an 
extensive discussion that strengthened his knowledge of the medication and increased his 
appreciation of the importance of adherence. 
Mow et al. [4] were the first investigative group to associate increased levels of immune 
response with complications of Crohn’s disease. Specifically, these investigators showed 
that specific serologic markers are present in patients with a more aggressive disease 
phenotype, in whom both the number and level of antibody responses were significantly 
associated with an increased likelihood of fibrostenosis, internal perforating disease, and 
the need for small bowel surgery. Arnott et al. [5] also found an association between 
immune responses to ASCA, anti-I2, anti-OmpC, and pANCA in patients with a more 
severe Crohn’s disease phenotype that included small bowel disease, longer duration of 
disease, a higher risk for progression, and the need for intestinal surgery. Similar 
correlations between the number and level of immune response and more severe disease 
phenotype have been observed in the pediatric population as well [6, 7]. 
The IBD Serology 7 results obtained in this case served as a valuable tool for overall 
disease management and facilitated physician-patient communication on disease 
prognosis and a continued need for therapy. The results yielded useful data to help ensure 
duration of therapy and adherence. 
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Table 1. Levels of serum biomarkers and reference values in a patient diagnosed with IBD and, 
specifically, Crohn's disease as measured by enzyme-linked immunosorbent assay 
Assay (EU/ml)  Patient  Reference 
ASCA IgA  032.7 <20.0 
ASCA IgG  095.6 <40.0 
Anti-OmpC IgA  016.7 <16.5 
Anti-CBir1 108.4  <21.0 
IBD-specific pANCA     
Autoantibody  049.5 <12.1 
Perinuclear pattern* detected  not  detected 
DNAse sensitivity  DNAse-sensitive  not detected 
* Measured by immunofluorescence assay. ASCA IgA and IgG = Anti-Saccharomyces cerevisiae 
antibody immunoglobulin A and G; anti-OmpC = antibodies to outer membrane porin C of Escherichia 
coli; anti-CBir1 = antibody against CBir1; pANCA = perinuclear antineutrophil cytoplasmic antibody. 
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Fig. 1. A colonoscopy in November 2008 demonstrated ulcerations of the ileum and colon consistent 
with Crohn’s disease. A stenotic ileum allowed only the distal few centimeters to be viewed. The 
physician initiated induction therapy with adalimumab 160 mg s.c., then 80 mg s.c. 2 weeks later, 
followed by maintenance therapy at a dose of 40 mg s.c. every 2 weeks. 
 
 
 
Fig. 2. A follow-up colonoscopy in March 2009 after a regimen of adalimumab demonstrated healing of 
the colonic mucosa and ileum. An inflammatory polyp at the ileocecal valve was removed. 
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Abbreviations: anti-CBir1 = antibody against CBir1; anti-I2 = antibodies against Pseudomonas 
fluorescens; anti-OmpC = antibodies against outer membrane porin C of Escherichia coli; ASCA IgA and 
IgG = anti-Saccharomyces cerevisiae antibody immunoglobulin A and G; pANCA = perinuclear 
antineutrophil cytoplasmic antibody. 